PLoS ONE · 2019 · 10 citations · 32 references
Public HealthBiostatisticsOncologyCancer EpidemiologyEpidemiologySurvival AnalysisCancer Survival AnalysisPrognostic AssessmentRisk PredictionSurvival ModelingSurvival OutcomesSurvival PredictionCancer Prognostic ModelingCancer Risk Prediction ModelsDisease Risk PredictionHuman Papillomavirus StatusLogistic RegressionMultivariable Risk Prediction ModelsPatient-specific Prognosis ModelingPrognostic Factors Analysis
BACKGROUND: HPV-16-positive HNSCC and HPV-16-negative HNSCC have different clinical factors, representing distinct forms of cancers. The study aimed to identify patient-specific factors for HPV-16-positive HNSCC based on baseline clinical data. METHOD: Factors associated with HPV-16-positive HNSCC were identified using the data from 210 patients diagnosed with HNSCC at University College of London Hospital between January 1, 2003, and April 30, 2015, inclusive. A series of models were developed using logistic regression methods, and the overall model fit was compared using Akaike Information Criterion. Survival analysis was carried with Cox proportional hazards model for survival-time outcomes. The survival time for individual patients was defined as the time from diagnosis of HNSCC to the date of death from any cause. For patients who did not die, they were censored at the end of study on April 30, 2015. RESULTS: Of the 210 patients, 151 (72%) were found to have HPV-16-positive HNSCC. The logistic regression model showed that the prevalence of developing HPV-16-positive HNSCC was 3.79 times higher in patients with Type 2 Diabetes Mellitus (T2DM) (odd ratio [OR], 3.79; 95% CI, 1.70-8.44) than in those without T2DM, and 8.84 times higher in patients with history of primary HNSCC (OR, 8.84; 95% CI, 2.30-33.88) than in those without a history of primary HNSCC. HPV-16-positive HNSCC was also observed more in tonsils (OR, 4.02; 95% CL, 1.56-10.36) and less in non-alcohol drinker's oral cavity (OR, 0.14; 95% CI, 0.03-0.56). Furthermore, individual patients were followed-up for 1 to 13 years (median of 1 year). Patients with HPV-positive HNSCC had a median survival of 5 years (95% CI, 2.6-7.3 years). Among HPV-16-positive HNSCC cohort, T2DM was a risk for poorer prognosis (hazard ratio, 2.57; 95% Cl, 1.09-6.07), and had lower median survival of 3 years (95% CI, 1.8-4.1 years), as compared to 6 years (95% CI, 2.8-9.1 years) in non-T2DM. CONCLUSIONS: Patient-specific factors for HPV-positive HNSCC are T2DM, history of primary HNSCC and tonsillar site. T2DM is associated with poorer prognosis. These findings suggest that it might be beneficial if routine HPV-16 screening is carried out in T2DM patients which can provide better therapeutic and management strategies.
32
Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer
Gypsyamber DʼSouza, Aimée R. Kreimer, Raphael P. Viscidi et al. · New England Journal of Medicine · 2007 · 2.7K citations
Medicine, Oncology, Cancer Control +13
Emma Ahlqvist, Petter Storm, Annemari Käräjämäki et al. · The Lancet Diabetes & Endocrinology · 2018 · 2.3K citations · Full text
Maura L. Gillison, Gypsyamber DʼSouza, William H. Westra et al. · JNCI Journal of the National Cancer Institute · 2008 · 1.5K citations · Full text
A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure
Navdeep Tangri · JAMA · 2011 · 1.3K citations
Medicine, Biostatistics, Nephrology +17